Summit Therapeutics Inc. Debt Securities Available For Sale Excluding Accrued Interest
Summit Therapeutics Inc. (SMMT) had Debt Securities Available For Sale Excluding Accrued Interest of $605.78 million as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-07-23
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $605.78M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $590.49M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $697.08M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $233.68M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest | Debt Securities Available For Sale Excluding Accrued Interest as first filed |
|---|---|---|
| 2026-06-30 | $605.78M 10-Q · filed 2026-07-23 | |
| 2026-03-31 | $590.49M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $697.08M 10-Q · filed 2026-07-23 | |
| 2025-09-30 | $233.68M 10-Q · filed 2025-10-20 | |
| 2025-06-30 | $293.61M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $353.63M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $396.09M 10-K · filed 2026-02-23 | $307.49M 10-K · filed 2025-02-24 |
| 2024-09-30 | $393.12M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $297.04M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $95.39M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $114.82M 10-K · filed 2025-02-24 | |
| 2023-09-30 | $175.15M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $172.90M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $170.96M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |